Eagle Pharmaceuticals completed its previously announced acquisition of Acacia Pharma Group plc in a deal that was valued at 94.7 million euros ($103.9 million) when it was disclosed March 28.

The closing was announced June 9.

The move adds two U.S. Food & Drug Administration-approved products to Woodcliff Lake-based Eagle’s portfolio: Barhemsys, used for the treatment of postoperative nausea and vomiting, and Byfavo, for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Combined, these products have an estimated $3.1 billion per year addressable market and projected annual peak sales of $2.752 billion in the U.S. The addition is expected to be earnings accretive in 2024.

“The closing of this transaction is a great achievement for Eagle both strategically and financially. The addition of the two products expands our presence in the acute care space, and we believe that our highly capable hospital-based salesforce will have great success commercializing these assets. We believe BARHEMSYS and BYFAVO represent two compelling opportunities, as both address significant unmet clinical needs,” Eagle President and CEO Scott Tarriff said in a statement.

Tarriff — who recently sat down with NJBIZ to talk about the acquisition — added that the deal brings Eagle’s commercial product count to eight, “with a ninth on the horizon if the new drug application submitted for landiolol last month is approved.”

The deal was closed by way of a scheme of arrangement under Part 26 of the U.K. Companies Act 2006; Acacia is based in Duxford, U.K.

Cooley (UK) LLP acted as legal advisor and William Blair & Co. LLC acted as exclusive financial advisor to Eagle in connection with the transaction. Locust Walk served as a transaction advisor to Eagle. NautaDutilh BV acted as legal advisor to Eagle in connection with Belgian law.